MiniMed Group offers attractive valuation at a forward P/E of 21.7 times with a PEG of 0.14 and solid Piotroski balance-sheet health, but two consecutive earnings misses, RSI at 78 with volume distribution, an elevated put/call ratio of 3.00, and business quality below the minimum floor create a setup where near-term execution risk dominates the statistical cheapness.
Thesis pillars
- Quality Below Minimum Threshold→Stable
- Elevated Bearish Options Positioning→Stable
- Consecutive Earnings Miss Track Record→Stable
- +1 more pillar — see the Why tab for full reasoning
MiniMed Group, Inc. (MMED) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $15.30: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality.
MiniMed Group, spun off from Medtronic, develops automated insulin delivery systems - including the MiniMed 780G and MiniMed Flex pumps paired with Guardian, Simplera and Instinct continuous glucose monitors - alongside the InPen smart insulin pen, competing globally against... Read more
Sell if holding. Engine safety override at $15.30: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 42d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-07-07Recent Developments — MiniMed Group, Inc.
Latest news
- NEWS MiniMed launches MiniMed Go smart multiple daily injection system in US - MassDevice — MassDevice positive
- NEWS MiniMed Group Q4 Earnings Call Highlights - MarketBeat — MarketBeat positive
- NEWS Earnings call transcript: MiniMed sees strong Q4 2026 growth, stock rises - Investing.com — Investing.com positive
- NEWS MiniMed (MMED) Reports Strong Q4 Revenue Growth - GuruFocus — GuruFocus positive
- NEWS MMED Projects 16% Adjusted EBITDA Margin by FY27 - GuruFocus — GuruFocus positive
Generated 2026-07-07T11:41:56Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierConvatec, Forj Medical and Steris sole-source suppliers10-K Item 1A: 'Our sole suppliers include Convatec Group plc for the infusion sets used in our insulin pumps, Forj Medical (f/k/a Intricon Corporation) for transmitters, and Steris plc and Steri-Tech Inc. for sterilization services.'
Material Events(8-K, last 90d)
- 2026-06-29Item 5.02LOWMiniMed's Board increased its size from nine to 11 members and appointed David Endicott (CEO of Alcon) and Linnea Burman as new independent directors, effective June 29, 2026.SEC filing →
- 2026-05-17Item 5.02MEDIUMDirector Brett Wall notified the Board he will resign effective July 3, 2026, following his departure as EVP and President, Neuroscience Portfolio at parent Medtronic plc, which had nominated him; Scott Cundy, a Medtronic SVP, was appointed to fill the vacancy effective the same date.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -10.7%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.30: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $14.22. Score 5.6/10, moderate confidence.
Take-profit target: $18.19 (+19.0% upside). Prior stop was $14.22. Stop-loss: $14.22.
Concentration risk — Supplier: Convatec, Forj Medical and Steris sole-source suppliers; Quality below floor (3.5 < 4.0).
MiniMed Group, Inc. trades at a P/E of N/A (forward 22.9). TrendMatrix value score: 7.1/10. Verdict: Sell.
18 analysts cover MMED with a consensus score of 4.2/5. Average price target: $21.
What does MiniMed Group, Inc. do?MiniMed Group, spun off from Medtronic, develops automated insulin delivery systems - including the MiniMed 780G and...
MiniMed Group, spun off from Medtronic, develops automated insulin delivery systems - including the MiniMed 780G and MiniMed Flex pumps paired with Guardian, Simplera and Instinct continuous glucose monitors - alongside the InPen smart insulin pen, competing globally against Dexcom, Insulet, Tandem and Beta Bionics. The company depends on sole suppliers for infusion sets, transmitters and sterilization services, a dependency highlighted by a January 2026 FDA warning letter to its infusion-set manufacturer.